MXPA03004394A - Profarmacos de cianoguanidina. - Google Patents

Profarmacos de cianoguanidina.

Info

Publication number
MXPA03004394A
MXPA03004394A MXPA03004394A MXPA03004394A MXPA03004394A MX PA03004394 A MXPA03004394 A MX PA03004394A MX PA03004394 A MXPA03004394 A MX PA03004394A MX PA03004394 A MXPA03004394 A MX PA03004394A MX PA03004394 A MXPA03004394 A MX PA03004394A
Authority
MX
Mexico
Prior art keywords
optionally substituted
branched
straight
halogen
hydrocarbon radical
Prior art date
Application number
MXPA03004394A
Other languages
English (en)
Spanish (es)
Inventor
Ernst Torndal Binderup
Original Assignee
Leo Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma As filed Critical Leo Pharma As
Publication of MXPA03004394A publication Critical patent/MXPA03004394A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MXPA03004394A 2000-11-21 2001-11-14 Profarmacos de cianoguanidina. MXPA03004394A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25207800P 2000-11-21 2000-11-21
PCT/DK2001/000750 WO2002042265A2 (en) 2000-11-21 2001-11-14 Cyanoguanidine prodrugs

Publications (1)

Publication Number Publication Date
MXPA03004394A true MXPA03004394A (es) 2004-04-20

Family

ID=22954502

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03004394A MXPA03004394A (es) 2000-11-21 2001-11-14 Profarmacos de cianoguanidina.

Country Status (16)

Country Link
US (1) US6525077B2 (cg-RX-API-DMAC7.html)
EP (2) EP1339686B1 (cg-RX-API-DMAC7.html)
JP (1) JP4521157B2 (cg-RX-API-DMAC7.html)
KR (1) KR100871577B1 (cg-RX-API-DMAC7.html)
CN (1) CN100368401C (cg-RX-API-DMAC7.html)
AU (3) AU1494702A (cg-RX-API-DMAC7.html)
BR (1) BR0115514A (cg-RX-API-DMAC7.html)
CA (1) CA2426601C (cg-RX-API-DMAC7.html)
CZ (1) CZ305764B6 (cg-RX-API-DMAC7.html)
ES (2) ES2549260T3 (cg-RX-API-DMAC7.html)
HU (1) HU230544B1 (cg-RX-API-DMAC7.html)
IL (2) IL155483A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA03004394A (cg-RX-API-DMAC7.html)
PL (1) PL224371B1 (cg-RX-API-DMAC7.html)
RU (1) RU2312858C2 (cg-RX-API-DMAC7.html)
WO (2) WO2002042265A2 (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711123D0 (en) * 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
US20030045515A1 (en) * 2001-05-24 2003-03-06 Lise Binderup Combination medicament for treatment of neoplastic diseases
PL228742B1 (pl) * 2002-05-17 2018-05-30 Leo Pharma As Proleki cyjanoguanidynowe, kompozycja farmaceutyczna zawierająca te proleki oraz związki pośrednie
US7253193B2 (en) 2002-05-17 2007-08-07 Leo Pharma A/S Cyanoguanidine prodrugs
WO2003097602A1 (en) * 2002-05-17 2003-11-27 Leo Pharma A/S Cyanoguanidine produgs
US20050101576A1 (en) * 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
WO2004089925A1 (en) * 2003-04-03 2004-10-21 Semafore Pharmaceuticals, Inc. Pi-3 kinase inhibitor prodrugs
US8053446B2 (en) 2004-12-22 2011-11-08 Leo Pharma A/S Cyanoguanidine compounds
WO2007022964A2 (de) 2005-08-24 2007-03-01 Abbott Gmbh & Co. Kg Hetaryl substituierte guanidinverbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
EP2197443A4 (en) * 2007-09-26 2014-01-01 Gemin X Pharmaceuticals Canada Inc COMPOSITIONS AND METHOD FOR LEADING NAD + MIRRORS USING A NICOTINAMIDE PHOSPHORIBOSYL TRANSFERASE HEMMER
US8173677B2 (en) * 2007-09-26 2012-05-08 Gemin X Pharmaceuticals Canada Inc. Compositions and methods for effecting NAD+ levels using a nicotinamide phosphoribosyl transferase inhibitor
US8101606B2 (en) 2007-11-12 2012-01-24 Washington University Neurofibromin pathway modulators
CN102186822A (zh) 2008-08-29 2011-09-14 顶标公司 新脲和硫脲衍生物
WO2010088842A1 (zh) 2009-02-06 2010-08-12 天津和美生物技术有限公司 含有吡啶基氰基胍的药物组合物及其制备和应用
EP2453883A1 (en) 2009-07-17 2012-05-23 Topo Target A/S Method for predicting the utility of administering nicotinic acid or a precursor or prodrug thereof to reduce the severity of side-effects of cancer treatment with nicotinamide phosphoribosyltransferase inhibitors
US9224007B2 (en) * 2009-09-15 2015-12-29 International Business Machines Corporation Search engine with privacy protection
US9600134B2 (en) 2009-12-29 2017-03-21 International Business Machines Corporation Selecting portions of computer-accessible documents for post-selection processing
US8912184B1 (en) 2010-03-01 2014-12-16 Alzheimer's Institute Of America, Inc. Therapeutic and diagnostic methods
WO2011121055A1 (en) 2010-03-31 2011-10-06 Topotarget A/S Pyridinyl derivatives comprising a cyanoguanidine or squaric acid moiety
AR082886A1 (es) 2010-09-03 2013-01-16 Forma Therapeutics Inc Compuestos y composiciones farmaceuticas que los contienen
US9359376B2 (en) * 2011-04-08 2016-06-07 Sphaera Pharma Pte. Ltd Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds
US9195853B2 (en) 2012-01-15 2015-11-24 International Business Machines Corporation Automated document redaction
WO2013188813A2 (en) * 2012-06-15 2013-12-19 The Regents Of The University Of California Novel therapeutics for brain cancer
SG11201408770RA (en) * 2012-06-27 2015-01-29 Alzheimer S Inst Of America Inc Compounds and therapeutic uses thereof
EP2903979B1 (en) 2012-10-04 2020-08-19 Inhibikase Therapeutics, Inc. Novel compounds, their preparation and their uses
US9892278B2 (en) 2012-11-14 2018-02-13 International Business Machines Corporation Focused personal identifying information redaction
US10227333B2 (en) 2015-02-11 2019-03-12 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
EA039121B1 (ru) 2015-02-27 2021-12-07 Куртана Фармасьютикалс, Инк. ИНГИБИРОВАНИЕ АКТИВНОСТИ Olig2
WO2017162536A1 (en) 2016-03-21 2017-09-28 H. Lundbeck A/S Vortioxetine prodrugs
WO2018199174A1 (ja) * 2017-04-25 2018-11-01 生化学工業株式会社 第3級アミン化合物又はイミン化合物-ポリマーコンジュゲートとその製造方法
EP3590927A1 (en) * 2018-07-05 2020-01-08 Bayer Animal Health GmbH Novel compounds for controlling arthropods
US11174229B2 (en) * 2018-10-29 2021-11-16 Kempharm, Inc. D-amphetamine compounds, compositions, and processes for making and using the same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0479951A4 (en) * 1989-06-26 1992-12-09 The Research Foundation Of State University Of New York Bis-acyloxymethyl derivatives
GB9219472D0 (en) 1992-09-15 1992-10-28 Leo Pharm Prod Ltd Chemical compounds
GB9607219D0 (en) * 1996-04-04 1996-06-12 Smithkline Beecham Plc Novel compounds
GB9711119D0 (en) 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
GB9711124D0 (en) 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
GB9711123D0 (en) 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
GB9711125D0 (en) 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
WO2000061561A1 (en) 1999-04-09 2000-10-19 Shionogi Bioresearch Corp. Cyanoguanidine compounds
AU4076500A (en) * 1999-04-09 2000-11-14 Shionogi Bioresearch Corp. (n)-substituted cyanoguanidine compounds

Also Published As

Publication number Publication date
BR0115514A (pt) 2003-12-30
JP4521157B2 (ja) 2010-08-11
ES2549260T3 (es) 2015-10-26
HU230544B1 (hu) 2016-11-28
WO2002042276A1 (en) 2002-05-30
PL362864A1 (en) 2004-11-02
US6525077B2 (en) 2003-02-25
HUP0400564A3 (en) 2008-03-28
IL155483A (en) 2010-12-30
EP1339686B1 (en) 2015-09-16
KR20030051861A (ko) 2003-06-25
EP2894149A1 (en) 2015-07-15
ES2643083T3 (es) 2017-11-21
US20020165201A1 (en) 2002-11-07
PL224371B1 (pl) 2016-12-30
WO2002042265A2 (en) 2002-05-30
AU2002214947B2 (en) 2007-02-15
KR100871577B1 (ko) 2008-12-02
IL155483A0 (en) 2003-11-23
CN100368401C (zh) 2008-02-13
CA2426601C (en) 2015-01-13
CZ305764B6 (cs) 2016-03-09
JP2004520282A (ja) 2004-07-08
RU2312858C2 (ru) 2007-12-20
HK1212678A1 (en) 2016-06-17
EP2894149B1 (en) 2017-08-02
WO2002042265A3 (en) 2002-08-15
EP1339686A2 (en) 2003-09-03
AU2002223511A1 (en) 2002-06-03
AU1494702A (en) 2002-06-03
HK1073297A1 (zh) 2005-09-30
HUP0400564A2 (hu) 2004-06-28
CZ20031303A3 (en) 2004-04-14
CN1589262A (zh) 2005-03-02
CA2426601A1 (en) 2002-05-30

Similar Documents

Publication Publication Date Title
WO2002042265A3 (en) Cyanoguanidine prodrugs
WO2022235935A3 (en) Ionizable cationic lipids for rna delivery
PE20251288A1 (es) Compuestos heterociclicos como inmunomoduladores
NZ324007A (en) Quinazoline derivatives susbtituted by a phenyl and medicaments
BR0111377A (pt) Derivados de tiofeno úteis como agentes anticancerìgenos
PH12021551257A1 (en) Cyclic pantetheine derivatives and uses thereof
BRPI0409938A (pt) derivados de azetidinacarboxamida e seu uso em terapia
NO20040945L (no) Benzotiepin ileal gallesyre transport inhibitorer
NO305209B1 (no) N-alkyl-2-substituerte ATP-analoger, slike forbindelser til fremstilling av terapeutikum, farmas°ytisk preparat inneholdende slike forbindelser, og deres anvendelse
MY133473A (en) Haterocyclic glycyl beta-alanine derivatives.
NO20052802L (no) Pyrrolopyrimidinderivativer
EA200100600A3 (ru) Новые соединения дифенилмочевины, способ их получения и содержащие их фармацевтические композиции
MY139446A (en) Novel quinoline derivatives
CR20230413A (es) Moduladores de sting (estimulador de genes de interferón)
DE60233656D1 (de) Pyridylcyanoguanidin verbindungen
AR034120A1 (es) Compuesto derivado halogenado del acido 2-amino-4,5 heptenoico, composicion farmaceutica que lo comprende y el uso de dicho compuesto y dicha composicion en la fabricacion de un medicamento para inhibir o modular la sintesis de acido nitrico
CY1111909T1 (el) Παραγωγα [[2-(αμινο-3,4-διοξο-1-κυκλοβουτεν-1-υλ)amino] αλκυλ]-οξεος για τη θεραπεια του πονου
PL378223A1 (pl) Nowe związki
UY27685A1 (es) Indolil-urea derivados de tienopiridinas útiles como agentes antiangiogénicos, y procedimientos para su uso
TR200101711T2 (tr) Antihistaminik spiro bileşikler.
MY122147A (en) Water soluble azoles as broad-spectrum antifungals
MY138466A (en) Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders
CY1109950T1 (el) Νεα παραγωγα 4,4-διθειοδις-(3-αμινοβουτανιο-1-σουλφονικων) και συνθεσεις που τα περιεχουν
BR0313000A (pt) Compostos, composição farmacêutica e método para efetuar a inibição da enzima pde4, realçar a cognição e/ou tratar a psicose em um paciente
BR9910206A (pt) Derivados de higromicina a.

Legal Events

Date Code Title Description
FG Grant or registration